blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1775306

EP1775306 - ckrox peptides and analogs thereof for treating skin ageing [Right-click to bookmark this link]
Former [2007/16]cKrox peptides and analogs thereof for treating skin ageing
[2008/49]
StatusNo opposition filed within time limit
Status updated on  12.02.2010
Database last updated on 19.07.2024
Most recent event   Tooltip07.10.2011Lapse of the patent in a contracting state
New state(s): CY, TR		published on 09.11.2011  [2011/45]
Applicant(s)For all designated states
Johnson & Johnson Consumer France SAS
1, rue Camille Desmoulins
92787 Issy les Moulineaux Cedex 9 / FR
[2007/16]
Inventor(s)01 / Oddos, Thierry
9, rue du professeur
92190 Meudon / FR
02 / Bellemere, Gaëlle
APPT 93 7, Rue Berlioz
76000 Rouen / FR
 [2009/15]
Former [2007/16]01 / Oddos, Thierry
9, rue du professeur
92190 Meudon / FR
02 / Bellemere, Gaelle
APPT 93 7, Rue Berlioz
76000 Rouen / FR
Representative(s)Metten, Karl-Heinz, et al
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
[N/P]
Former [2007/16]Metten, Karl-Heinz, et al
Forrester & Boehmert, Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date05292121.011.10.2005
[2007/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1775306
Date:18.04.2007
Language:EN
[2007/16]
Type: B1 Patent specification 
No.:EP1775306
Date:08.04.2009
Language:EN
[2009/15]
Search report(s)(Supplementary) European search report - dispatched on:EP28.03.2006
ClassificationIPC:C07K7/06, A61K38/08
[2007/16]
CPC:
C07K14/4702 (EP,US); A61P17/00 (EP); C07K7/06 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/16]
TitleGerman:ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung[2007/16]
English:ckrox peptides and analogs thereof for treating skin ageing[2008/49]
French:Peptides de ckrox et leurs analogues pour le traitement du vieillissement cutane[2007/16]
Former [2007/16]cKrox peptides and analogs thereof for treating skin ageing
Examination procedure17.10.2007Examination requested  [2007/48]
20.11.2007Despatch of a communication from the examining division (Time limit: M06)
30.05.2008Reply to a communication from the examining division
03.11.2008Communication of intention to grant the patent
25.02.2009Fee for grant paid
25.02.2009Fee for publishing/printing paid
Opposition(s)11.01.2010No opposition filed within time limit [2010/11]
Fees paidRenewal fee
12.10.2007Renewal fee patent year 03
31.03.2008Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.04.2009
BE08.04.2009
CY08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
IT08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
TR08.04.2009
BG08.07.2009
SE08.07.2009
GR09.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
HU09.10.2009
IE11.10.2009
LU11.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
[2011/44]
Former [2011/32]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
IT08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
BG08.07.2009
SE08.07.2009
GR09.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
HU09.10.2009
IE11.10.2009
LU11.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
Former [2011/21]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
IT08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
BG08.07.2009
SE08.07.2009
GR09.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
IE11.10.2009
LU11.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
Former [2011/15]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
IT08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
BG08.07.2009
SE08.07.2009
GR09.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
IE11.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
Former [2010/46]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
BG08.07.2009
SE08.07.2009
GR09.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
IE11.10.2009
CH31.10.2009
LI31.10.2009
MC31.10.2009
Former [2010/25]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
BG08.07.2009
SE08.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
MC31.10.2009
Former [2010/18]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
BG08.07.2009
SE08.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
Former [2010/12]AT08.04.2009
BE08.04.2009
CZ08.04.2009
DK08.04.2009
EE08.04.2009
FI08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
RO08.04.2009
SI08.04.2009
SK08.04.2009
SE08.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
Former [2010/01]AT08.04.2009
FI08.04.2009
LT08.04.2009
LV08.04.2009
NL08.04.2009
PL08.04.2009
SI08.04.2009
SE08.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
Former [2009/51]AT08.04.2009
FI08.04.2009
LT08.04.2009
NL08.04.2009
SI08.04.2009
SE08.07.2009
ES19.07.2009
IS08.08.2009
PT08.09.2009
Former [2009/48]LT08.04.2009
SI08.04.2009
ES19.07.2009
Former [2009/46]SI08.04.2009
ES19.07.2009
Former [2009/45]SI08.04.2009
Documents cited:Search[A]US2005065090  (LUDIN CHRISTIAN [CH], et al);
 [X]  - TAMURA T ET AL, "ANTIBODIES AGAINST SYNTHETIC PEPTIDES AS A TOOL FOR FUNCTIONAL ANALYSIS OF THE TRANSFORMING PROTEIN PP-60-SRC", CELL, (1983), vol. 34, no. 2, ISSN 0092-8674, pages 587 - 596, XP002367811 [X] 1,2,8,9 * Table 1, peptide KKGERL (A4-A9). *

DOI:   http://dx.doi.org/10.1016/0092-8674(83)90391-4
 [X]  - "Homo sapiens Ig gene V segment, D segment, and J segment.", EMBL, (19951001), Database accession no. L37848, URL: EBI, XP002367817 [X] 1,2,8,9 * Peptide TKG *
 [X]  - "transthyretin [human, Genomic Mutant, 9 nt].", EMBL, (19931124), Database accession no. S60148, URL: EBI, XP002367818 [X] 1,2,8,9 * Peptide TRG *
 [X]  - "Chlamydomonas reinhardtii strain CC-2290 AC206 (AC206) gene, 3' UTR and partial cds.", EMBL, (20040218), Database accession no. AY453426, URL: EBI, XP002367819 [X] 1,2,8,9 * Peptide AKQ *
 [X]  - "Homo sapiens Ig gene V segment, D segment, and J segment.", EMBL, (19951001), Database accession no. L37861, URL: EBI, XP002367820 [X] 1,2,8,9 * Peptide ARG *
 [AD]  - GALERA PHILIPPE ET AL, "C-Krox, a transcriptional regulator of type I collagen gene expression, is preferentially expressed in skin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1994), vol. 91, no. 20, ISSN 0027-8424, pages 9372 - 9376, XP002367812

DOI:   http://dx.doi.org/10.1073/pnas.91.20.9372
by applicantUS2005065090
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.